EHA 2023 | Optimizing the use of FLT3 inhibitors in AML: sequencing, post-transplant maintenance & more
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, comments on some of the questions and debates surrounding the use of FLT3 inhibitors in acute myeloid leukemia (AML), discussing optimal FLT3 inhibitor sequencing, resistance mechanisms to these agents, their use as a maintenance therapy post-transplantation, and their role in unfit patients with AML. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy, Honoraria, Other: Travel Expenses; Astellas: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Travel Expenses; Pfizer: Consultancy
